TNF and uveitis: All TNF-α inhibitors demonstrated strong signals for uveitis (ROR = 23.89, 95% CI [20.16–28.22], n = 308), particularly adalimumab (ROR = 20.96, 95% CI [17.82–24.65], n = 145) and golimumab (ROR = 52.08, 95% CI [31.07–87.33], n = 15).